These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37877283)

  • 1. Hepatic steatosis after switching to integrase inhibitor-based regimens does not parallel short-term weight gain.
    Gonzalez-Serna A; Macías J; Rincon P; Arriaza MJ; Corma-Gomez A; Santos M; Fernandez-Fuertes M; Pineda JA; Real LM
    AIDS; 2023 Nov; 37(14):2259-2262. PubMed ID: 37877283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
    Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
    J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens.
    Milic J; Renzetti S; Ferrari D; Barbieri S; Menozzi M; Carli F; Dolci G; Ciusa G; Mussini C; Calza S; Guaraldi G
    AIDS; 2022 Oct; 36(12):1643-1653. PubMed ID: 35727163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
    Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
    Macías J; Mancebo M; Merino D; Téllez F; Montes-Ramírez ML; Pulido F; Rivero-Juárez A; Raffo M; Pérez-Pérez M; Merchante N; Cotarelo M; Pineda JA;
    Clin Infect Dis; 2017 Sep; 65(6):1012-1019. PubMed ID: 28903510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants.
    Verboeket SO; Boyd A; Wit FW; Verheij E; Schim van der Loeff MF; Kootstra N; van der Valk M; Reiss P;
    PLoS One; 2021; 16(5):e0251205. PubMed ID: 33951089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients.
    Macías J; Real LM; Rivero-Juárez A; Merchante N; Camacho A; Neukam K; Rivero A; Mancebo M; Pineda JA
    HIV Med; 2016 Nov; 17(10):766-773. PubMed ID: 27028546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased Hepatic Steatosis in South African Adolescents With Perinatal HIV Switching to Dolutegravir-containing Regimens.
    Rose PC; De la Rey Nel E; Cotton MF; Otwombe K; Browne SH; Frigati LJ; Rabie H; Innes S
    Pediatr Infect Dis J; 2023 Jul; 42(7):564-572. PubMed ID: 36917035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV.
    Burns JE; Stirrup OT; Dunn D; Runcie-Unger I; Milinkovic A; Candfield S; Lukha H; Severn A; Waters L; Edwards S; Gilson R; Pett SL
    AIDS; 2020 Jan; 34(1):109-114. PubMed ID: 31567162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled attenuation parameter accurately detects liver steatosis in people with HIV.
    Duarte M; Tien P; Ma Y; Noworolski SM; Korn N; Price JC
    AIDS; 2022 Dec; 36(15):2147-2152. PubMed ID: 35950941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight change with integrase strand transfer inhibitors among virally suppressed Thai people living with HIV.
    Han WM; Kerr SJ; Avihingsanon A; Boettiger DC
    J Antimicrob Chemother; 2022 Nov; 77(12):3242-3247. PubMed ID: 36101517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus.
    Asundi A; Olson A; Jiang W; Varshney SP; White LF; Sagar M; Lin NH
    AIDS Res Hum Retroviruses; 2022 Mar; 38(3):208-215. PubMed ID: 34877881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease.
    Calza L; Colangeli V; Borderi M; Coladonato S; Tazza B; Fornaro G; Badia L; Guardigni V; Verucchi G; Viale P
    Infect Dis (Lond); 2019 Aug; 51(8):593-601. PubMed ID: 31219362
    [No Abstract]   [Full Text] [Related]  

  • 14. Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy.
    Erlandson KM; Wu K; Lake JE; Samuels DC; Bares SH; Tassiopoulos K; Koethe JR; Brown TT; Leonard M; Benson CA; Haas DW; Hulgan T;
    AIDS; 2021 Mar; 35(3):439-445. PubMed ID: 33252493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus.
    Chow W; Donga P; Côté-Sergent A; Rossi C; Lefebvre P; Lafeuille MH; Emond B; Hardy H
    Curr Med Res Opin; 2020 Aug; 36(8):1313-1323. PubMed ID: 32459155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naïve adults.
    Burns JE; Stirrup O; Waters L; Dunn D; Gilson R; Pett SL
    HIV Med; 2022 Mar; 23(3):294-300. PubMed ID: 34634168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
    Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
    Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV.
    Guaraldi G; Calza S; Milic J; Calcagno A; Focà E; Rota M; Renzetti S; Celotti A; Siano M; Celesia BM; Piconi S; de Socio GV; Cattelan AM; Orofino G; Riva A; Nozza S; di Perri G
    AIDS; 2021 May; 35(6):939-945. PubMed ID: 33635844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.
    Leonard MA; Cindi Z; Bradford Y; Bourgi K; Koethe J; Turner M; Norwood J; Woodward B; Erdem H; Basham R; Baker P; Rebeiro PF; Sterling TR; Hulgan T; Daar ES; Gulick R; Riddler SA; Sinxadi P; Ritchie MD; Haas DW
    Clin Infect Dis; 2021 Oct; 73(7):e2153-e2163. PubMed ID: 32829410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight Gain in Incarcerated Individuals Living With HIV After Switching to Integrase Strand Inhibitor-Based Therapy.
    Goldberg RN; Kania AT; Michienzi SM; Patel M; Badowski ME
    J Int Assoc Provid AIDS Care; 2021; 20():2325958221996860. PubMed ID: 33626965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.